Jiangsu Hansoh Pharmaceutical Co., Ltd.

This study tests an experimental drug called HS-20136-2, given as an injection under the skin, to see if it is safe and tolerable in healthy and obese adults aged 18 to 55. The trial also looks at how the drug moves through the body and whether it causes weight changes. Participa…

This phase 3 study evaluates the safety of HS-10506, an experimental insomnia medication, in 600 Chinese adults aged 18 to 64 with insomnia disorder. Researchers track side effects, serious adverse events, and specific safety concerns over both short and long-term use. The goal i…

This early-stage study tests a new drug, HS-10541, in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The drug is given alone or with other cancer treatments. The main goals are to check safety, find the right dose, and see if it shrinks tu…

This early-stage study tests a new tablet called HS-10522 in healthy Chinese adults and those with mild hypertension. The main goal is to check safety and how the drug moves through the body. 88 participants will receive either the drug or a placebo to compare side effects and dr…

This early-stage trial tests a new drug called HS-10587 in people with advanced solid tumors that have lost a gene called MTAP. The study aims to find a safe dose and see if the drug can shrink tumors. About 362 participants who have exhausted standard treatments will take the dr…

This study tests a new medicine called HS-10390 in 182 adults with chronic kidney disease. The goal is to see if it can lower protein levels in urine, a sign of kidney damage, better than standard care. Participants must already be on stable blood pressure medication and have mod…

This Phase 2 trial tests an experimental drug called HS-10542 in 90 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. Participants will receive either a high dose, low dose, or placebo for a set period. The main goal is to see if the drug reduces prot…

This study tests a new treatment called HS-10566, a gel that delivers the chemotherapy drug gemcitabine directly into the bladder. It is for people with high-risk non-muscle-invasive bladder cancer who cannot or choose not to have their bladder removed. The trial will check if th…

This early-stage trial is testing a new oral drug called HS-10504 combined with several other drugs given by IV in people with advanced non-small cell lung cancer that has worsened after previous treatment. The study will enroll about 400 participants and aims to find safe doses …

This Phase 3 study tests a new drug called HS-20094, given as a weekly injection, in 204 adults with type 2 diabetes that is not well controlled by diet and exercise alone. Participants will receive either the drug or a placebo for up to 52 weeks. The main goal is to see if the d…

This Phase 3 study tests an experimental drug called HS-20094 against the standard drug dulaglutide, both given as weekly injections. About 546 adults with type 2 diabetes whose blood sugar is not well controlled on metformin or SGLT2 inhibitors will take part. The main goal is t…

This phase 3 study tests whether the drug HS-10506 helps Chinese adults with insomnia fall asleep faster and wake up less during the night. About 732 participants will receive either the drug or a placebo for up to 84 days. The study measures sleep using both overnight lab tests …

This phase 1 trial investigates how HS-10504, an experimental drug for EGFR-mutant non-small cell lung cancer, changes the way the body processes midazolam, a common sedative. About 24 patients with advanced lung cancer who have stopped responding to standard EGFR-targeted therap…

This early-stage study tests a new drug, HS-20136-2, in 38 healthy adults to see if it is safe and how the body handles it. Participants receive a single injection of either the drug or a placebo, and researchers monitor for side effects and measure drug levels in the blood. Sinc…

This early-stage trial will test 20 healthy Chinese adults to see if taking itraconazole (a common antifungal) changes how the body processes HS-10506, an experimental drug. Participants will take HS-10506 alone and then again with itraconazole. The goal is to measure drug levels…

This early-stage study tests the safety of a new drug called HS-20152 in 32 healthy adults aged 18 to 64. The drug targets the complement system, part of the body's immune response. Researchers will monitor for side effects and measure how the drug moves through the body. This st…